Balakrishna launches Basavatarakam cancer hospital works
The project, which faced significant delays after its initial foundation stone was laid in 2019, is now moving forward following the new state government's decision to clear all hurdles and allot an additional six acres of land. The new facility will be built on a total of 21 acres.
Speaking at the launch, Balakrishna explained that the new campus is envisioned as a 'Centre of Excellence' for comprehensive cancer treatment, research, and patient care. The facility will integrate cutting-edge medical technology with a multidisciplinary approach.
Balakrishna explained that the new facility is envisioned as a Centre of Excellence for comprehensive cancer treatment, research, and patient-centric care. The hospital will integrate cutting-edge medical technology with a multidisciplinary approach, delivered in a purpose-built modern facility, he added.
An initial investment of Rs 750 crore will establish a 500-bed facility, offering a broad spectrum of oncology services in the first phase. This phase will focus on infrastructure, advanced equipment, and clinical excellence, including precision diagnostics and treatment systems. Operations are expected to commence by 2028.
The second phase will add another 500 beds, bringing the total capacity to 1,000. It will include the development of specialised departments, research wings, and enhanced patient amenities, with the goal of creating a regional referral center for complex cancer cases.
The launch event was attended by several dignitaries, including Assembly Speaker Ch Ayyanna Patrudu, ministers P Narayana and Y Satya Kumar, along with MP Kesineni Shivnath, MLA Tenali Sravan Kumar, Dr Undavalli Sridevi and other prominent leaders and officials. Trust board members, including Dr Dattatreyudu Nori and Nara Brahmani, were also present.
In his remarks, Balakrishna expressed his gratitude to all donors and supporters, emphasising that the project would carry forward the hospital's legacy of compassion and excellence.
Dr. Senthil Rajappa, head of Medical Oncology, assured that medical services at the new facility would be operational by 2028.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Farmer dies by suicide, family blames crop failure
Balangir: A 46-year-old farmer died on Thursday after allegedly consuming poison with family members blaming crop failure and mounting debt for his death. The incident occurred in Kandara village under Titilagarh block of Balangir district. Tired of too many ads? go ad free now The deceased, Durga Charan Bhoi, had been under severe mental stress after failing to repay multiple loans, his family claimed. Bhoi allegedly took pesticide on Wednesday afternoon. Family members found him unconscious behind their house and took him to Sindhekela hospital, before he was shifted to Titilagarh hospital. As his condition worsened, he was moved to the district headquarters hospital in Bhawanipatna, where doctors pronounced him dead. Bhaskar Bhoi, the deceased's cousin, said, "My brother had borrowed over Rs 2 lakh from various self-help groups and banks for paddy and cotton cultivation. Crop failure made repayment impossible." Bhoi had cultivated paddy on 3 acres and cotton on 2 acres of land. Family members claimed the crops got damaged due to scanty rainfall. On Thursday, police launched a probe while senior revenue and agriculture officials met the bereaved family. The administration provided Rs 10,000 as immediate assistance and promised additional compensation as per govt provisions. Titlagarh tehsildar Subhashis Satapathy said, "We will conduct a thorough ground inquiry and take appropriate action based on our findings."
News18
3 hours ago
- News18
Allahabad HC stays fee hike for MBBS course by Hapur medical college
Agency: PTI Prayagraj, Aug 14 (PTI) The Allahabad High Court has stayed an increase in fee for the MBBS course by the GS Medical College in Hapur, and directed the state government and the college to file their reply within two weeks. The order was passed by Justice C D Singh on August 13 while hearing a petition filed by Aanya Porwal and 239 other MBBS students. The fee was increased mid-semester from Rs 11 lakh to 14 lakh. The counsel for the petitioners claimed the notification issued on July 5 by the state government was 'arbitrary" and 'without application of mind". The government, while issuing the aforesaid notification, failed to consider the other miscellaneous charges, which have already been enhanced during this session, the counsel argued. He said there was no reason to increase the fee for a second time in eight months, particularly when miscellaneous charges had already been deposited by the petitioners. The government's counsel submitted that it (fee hike) was done in accordance with the law, and there was no illegality or error in the impugned notification, saying the instant writ petition may be dismissed as devoid of any merit. The court said, 'Taking into consideration the submissions made by the learned counsel for the petitioners as well as the learned counsel for the respondent and the contents made in the writ petition, I am of the view that matter requires consideration." The court directed to put up the case on September 17, and till then the operation of the impugned notification dated July 5 shall be kept in abeyance. PTI COR RAJ ARI view comments First Published: August 14, 2025, 23:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hans India
6 hours ago
- Hans India
AstraZeneca Pharma India's net profit slips 4 pc in Q1
Mumbai: AstraZeneca Pharma India Limited on Thursday reported a 4.12 per cent decline in net profit for the first quarter (Q1) of FY26, with earnings falling to Rs 55.8 crore from Rs 58.2 crore in the previous quarter (Q4 FY25). This dip came despite a strong rise in revenue from operations, which grew 9.56 per cent sequentially to Rs 526.3 crore from Rs 480.4 crore, according to its stock exchange filing. Other income saw a sharp decline of 30.43 per cent, dropping to Rs 11.2 crore from Rs 16.1 crore in Q4 FY25. However, total income rose 8.23 per cent to Rs 537.5 crore from Rs 496.6 crore, driven by solid operational performance. Total expenses increased by 12.12 per cent to Rs 462.4 crore, compared to Rs 412.4 crore in the previous quarter, the company stated in its regulatory filing. Bhavana Agrawal, Chief Financial Officer and Director of the Company, said the strong quarterly performance reflects the power of science-led innovation combined with disciplined execution. 'Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases. We remain focused on expanding our portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most,' she added. Praveen Rao Akkinepally, Country President and Managing Director, said that delivering consistent growth across therapy areas reaffirms the strength of the company's 'Growth Through Innovation' strategy. 'These results are a testament to what is possible when science and purpose come together,' he noted. AstraZeneca, a global science-led biopharmaceutical company, focuses on the discovery, development, and commercialisation of prescription medicines, primarily in oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases. The company operates in over 100 countries, with its medicines used by millions of patients worldwide. Completing 45 years in India, AstraZeneca Pharma India Limited is headquartered in Bengaluru and employs over 600 people across the country.
